Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Metastatic breast cancer confirmed by biopsy~* Overexpression of the Her-2 oncogene~* Age \> 18 years~* Measurable disease~* Able to perform activities of daily living with minimal assistance~* No previous chemotherapy for metastatic disease~* One or more previous hormonal therapies for metastatic disease.~* Adequate bone marrow, liver and kidney function~* Patients with \< grade 1 peripheral neuropathy are eligible.~* Must give written informed consent prior to entering this study.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Abnormal heart function~* Previous treatment with trastuzumab~* Brain metastases untreated~* Pre-existing symptomatic peripheral neuropathy~* Serious underlying medical conditions~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).